- CN
- Latest stock price:
As announced by Athenex, Inc. (NASDAQ: ATNX), Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited (“XLifeSc"), the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell rec...
see details >>
Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue”) received news from Athenex, Inc. (Nasdaq: ATNX) that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of meta...
see details >>
Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue”) has expandedits strategic partnership with Athenex, Inc. (Nasdaq: ATNX) to exclusively developand commercialize Athenex’s oncology product candidates Oral Paclitaxel (boththe capsule and the tablet formulations), Oral Irinotecan, as well as...
see details >>
Source: Guangdong Medical Valley On October 16, the second award ceremony for the “top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "（“GBA"）was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as “XLifes"), a subsidiary of Gua...
see details >>
No. 2, Jinfengyuan Road, Science City,
Guangzhou Economic and Technological Development Zone
020-22211555
XPH Group
XLifeSc
Pharmaceutical
TCM Resources